5 Best Regional Bank Stocks To Invest In 2014

Regional bank Fifth Third Bancorp (FITB) reported a dip in its fourth quarter earnings on Thursday. Despite the fall in earnings, EPS remained unchanged and came in above analyst estimates.

FITB’s Earnings in Brief

The company reported Q4 earnings of�$402 million, down from $421 million a year ago. FITB’s �adjusted net income dipped to�$383 million from $390 million a year ago. On a per share basis, earnings remained unchanged at 43 cents per share. Analysts expected to see earnings of 42 cents per share. For FY2013, earnings rose 17% to�$1.8 billion, or $2.02 per share, up from $1.5 billion, or $1.66 per share, in 2012.

CEO Commentary

Top 10 Financial Stocks To Invest In 2015: Star Bulk Carriers Corp.(SBLK)

Star Bulk Carriers Corp. operates as a shipping company providing seaborne transportation solutions in the dry bulk sector worldwide. Its vessels transport major bulks, which include iron ore, coal, and grain; and minor bulks, such as bauxite, fertilizers, and steel products. The company has an operating fleet of 15 dry bulk carriers consisting of 7 Capesize and 8 Supramax dry bulk vessels with a combined cargo carrying capacity of 1,625,945 deadweight tons. The company was incorporated in 2006 and is based in Athens, Greece.

Advisors' Opinion:

• [By James E. Brumley]

  It's certainly no Safe Bulkers, Inc. (NYSE:SB) or Star Bulk Carriers Corp. (NASDAQ:SBLK), in terms or market cap or revenue. In fact, even with the drybulk shipping industry it's a somewhat obscure name. Yet, FreeSeas Inc. (NASDAQ:FREE) may well be the stock with the most near-term potential upside, now that it's gotten over a key technical hump.

• [By Roberto Pedone]

  Star Bulk Carriers (SBLK) provides worldwide transportation of drybulk commodities through its vessel-owning subsidiaries for a range of customers and minor bulk cargoes including iron ore, coal, grain, cement and fertilizer. This stock closed up 7.9% at $10.58 in Monday's trading session.

  Monday's Volume: 243,000
  
  Three-Month Average Volume: 64,367
  
  Volume % Change: 228%

  From a technical perspective, SBLK jumped sharply higher here right above some near-term support at $9.47 with above-average volume. This stock has been uptrending strong for the last two months and change, with shares moving higher from its low of $5.37 to its recent high of $11.53. During that move, shares of SBLK have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of SBLK within range of triggering a near-term breakout trade. That trade will hit if SBLK manages to take out its 52-week high at $11.53 and then once it clears some past resistance at $11.98 with high volume.

  Traders should now look for long-biased trades in SBLK as long as it's trending above near-term support at $9.47 and then once it sustains a move or close above those breakout levels with volume that hits near or above 64,367 shares. If that breakout triggers soon, then SBLK will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are its next major overhead resistance levels at $14 to $15.

• [By Igor Greenwald]

  Last month, Oaktree Capital (OAK), managed by another distressed investing icon, Howard Marks, disclosed a huge 21.9% stake in Star Bulk Carriers (SBLK).

• [By James E. Brumley]

  I'll warn you now that if you're a fan or shareholder of Star Bulk Carriers Corp. (NASDAQ:SBLK), then you're not going to like what you're about to read. Before you fly off into a tirade of "colorful" descriptions of me, however, know that this is neither a judgment call on the company itself, nor a long-term outlook. It's simply a trading-based observation of hints that SBLK has dropped today. Fair enough? OK, let's dig in.

5 Best Regional Bank Stocks To Invest In 2014: China Direct Industries Inc.(CDII)

CD International Enterprises, Inc. sources, produces, and distributes industrial products in the People?s Republic of China and the Americas. The company operates in three segments: Magnesium, Basic Materials, and Consulting. The Magnesium segment produces, sells, and distributes pure magnesium ingots, magnesium powder and granules, and magnesium scraps. The Basic Materials segment sells and distributes various products, including industrial grade synthetic chemicals, steel products, non-ferrous metals, recycled materials, and industrial commodities. The Consulting segment provides a range of consulting services to the U.S. public companies that operate primarily in China. This segment offers its services in the areas of financing structures and arrangements, mergers, acquisitions and other business transactions, identifying potential areas of growth, translation services, managing and coordinating necessary government approvals and licenses, marketing services, investor relations services, and coordination of the preparation of required SEC filings. The company was formerly known as China Direct Industries, Inc. and changed its name to CD International Enterprises, Inc. in February 2012. CD International Enterprises, Inc. is headquartered in Deerfield Beach, Florida.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks CD International Enterprises Inc (OTCMKTS: CDII), Creative Edge Nutrition Inc (OTCMKTS: FITX) and Metrospaces Inc (OTCMKTS: MSPC) have all been the subject of recent as well as past paid for stock promotions. Of course, there is nothing wrong with properly disclosed stock promotions or investor awareness campaigns, but they can and do often backfire on unwary investors and traders alike. With that in mind, will investors and traders come out winners with these small caps or should they just be left to the promoters? Here is a quick reality check:

  CD International Enterprises Inc (OTCMKTS: CDII) Has Been Busy Announcing New Deals

  Small cap CD International Enterprises is a US based company that produces, sources, and distributes industrial commodities in China and the Americas and provides business and financial corporate consulting services. On Friday, CD International Enterprises closed at $0.133 for a market cap of $7.60 million plus CDII is up 29% since the start of the year and down 91.4% over the past five years according to Google Finance.

5 Best Regional Bank Stocks To Invest In 2014: Etablissementen Fr Colruyt NV (COLR)

Etablissementen Fr Colruyt NV, also known as Colruyt Group, is a Belgian company primarily engaged in retail and wholesale of food products. The Company's retail trade division includes the direct supply of products to retail customers operating through brands Colruyt, DreamBaby, BIO-planet, DreamLand and ColliShop, among others. The Company supplies to wholesalers and affiliated independent merchants in Belgium, France and Luxembourg. It also provides printing solutions (photo Fuji Colruyt). Colruyt Group also has a corporate activities division, which combines support services, processes and systems and central administration, among others. Advisors' Opinion:

• [By Tom Stoukas]

  Colruyt SA (COLR) fell 4 percent to 42.31 euros. Belgium�� largest discount food retailer forecast full-year net income of about 369 million euros ($498 million) compared with analysts�� estimates of 381.2 million euros.

5 Best Regional Bank Stocks To Invest In 2014: Infinity Pharmaceuticals Inc.(INFI)

Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for difficult-to-treat diseases. The company?s lead product candidates include saridegib (IPI-926), an oral molecule with the potential to treat a range of cancers by disrupting malignant activation of the Hedgehog pathway; and Retaspimycin HCl (IPI-504), a heat shock protein 90 (Hsp90) inhibitor. Its Saridegib is in a Phase II clinical trial for the treatment of metastatic or inoperable chondrosarcoma and a Phase II exploratory trial in patients with myelofibrosis. The company?s Retaspimycin HCl is in a Phase II trial in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC); and in a Phase Ib/II trial in combination with everolimus, known as Afinitor, in approximately 45 NSCLC patients with a KRAS mutation. Its pipeline also includes IPI-145, an inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) in Phase I development to treat in flammation and hematologic malignancies. Infinity Pharmaceuticals has a strategic alliance with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited to develop and commercialize pharmaceutical products; and a development and license agreement with Millennium to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K, including IPI-145. Purdue Pharmaceutical Products is planning to conduct Phase II studies of IPI-940 in pain. The company is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Ben Levisohn]

  Somaiya and team named Gilead and�Neurocrine Biosciences (NBIX) their top picks, hile putting Buy ratings on Celgene, Biogen Idec, Alexion (ALXN), Incyte (INCY), Pharmacyclics (PCYC) and Synageva (GEVA). BioMarin (BMRN), Infinity Pharmaceuticals (INFI) and Amgen (AMGN) earned Neutral ratings.